Investors
Investors

Message from CEO

“Key global products XTANDI and Betanis / Myrbetriq / BETMIGA (mirabegron) continued to demonstrate steady growth in the first six months of FY2017, and milestones such as the positive results from the Phase 3 PROSPER trial of enzalutamide in non-metastatic castration resistant prostate cancer patients demonstrate that our development activities are progressing steadily. Furthermore, continuous resource allocation is being made with the aim of realizing sustainable growth over the medium- and long-terms,” said Yoshihiko Hatanaka, president and CEO, Astellas. “We remain committed to creating innovative medical solutions and delivering value for patients and all stakeholders, as we continue to advance our strategic plan through maximizing the product value, creating innovation and pursuing operational excellence.”

Stock Quotes(TSE 1st:4503)

View Stock Performance

IR Library

This section contains IR related information for shareholders and investors. Various IR materials can be downloaded from here.

Read More

Stock & Rating Information

Year-end dividend - March 31 Interim dividend - September 30 Note: In accordance with the Company's Articles of Incorporation, if cash divid...

Read More

Analyst Coverage

List of analysts of securities companies and research companies who make recommendations and reports of Astellas' performance, etc

Read More

Cautionary Statement

The information disclosed in this part of the Astellas Website is provided for better understanding of Astellas by stakeholders including sh...

Read More